{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:44:49Z","timestamp":1783655089653,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pharmacosmos"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ferric derisomaltose (FDI; Monofer) is used in clinical practice to treat iron deficiency, but the safety and efficacy of FDI has not been robustly evaluated in a large real-world study. This retrospective, multicentre, audit-based, observational study provides pragmatic information about safety and clinical responses with FDI across therapy areas and patient populations, helping to facilitate treatment decisions. Participating sites provided data from the medical records of adults who had received\u2009\u2265\u20091 FDI infusion. The primary outcome was the incidence of adverse reactions within 24\u00a0hours of the FDI infusion. Secondary outcomes included the change from baseline in haemoglobin and ferritin up to 12\u00a0months post infusion. In total, 19 sites provided data for a total of 7354 FDI-treated patients; 64.3% of patients were female, and 42.2% were aged\u2009\u2265\u200970\u00a0years. Surgery was the main hospital specialty (34.5%). The incidence of any recorded adverse reactions, hypersensitivity reactions, and anaphylaxis were 1.7%, 0.4%, and\u2009&lt;\u20090.1%, respectively, regardless of baseline anaemia status. Statistically significant increases in haemoglobin and ferritin were observed between baseline and Month 4 following FDI treatment (p\u2009&lt;\u20090.0001). Improvements in haemoglobin were more pronounced for hospital specialties where operative blood loss is expected (surgery\/obstetrics) compared with those where blood loss is not expected. This study provides real-world clinical evidence for the low risk of adverse reactions with FDI across diverse patient populations, providing reassurance that intravenous iron is not associated with serious toxicity. These findings may inform changes in intravenous iron delivery to provide effective therapy to more patients in need.<\/jats:p>","DOI":"10.1038\/s41598-022-23581-3","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T11:40:50Z","timestamp":1667821250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK"],"prefix":"10.1038","volume":"12","author":[{"given":"Rhona C. F.","family":"Sinclair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Nadaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"23581_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. ESC Scientific Document Group: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"23581_CR2","unstructured":"National Institute for Health and Care Excellence (NICE). Blood transfusion. NICE guideline NG24. 2015. https:\/\/www.nice.org.uk\/guidance\/ng24\/resources\/blood-transfusion-pdf-1837331897029. Accessed 29 Mar 2022."},{"key":"23581_CR3","unstructured":"National Institute for Health and Care Excellence (NICE). Blood transfusion. NICE quality standard QS138. 2016. https:\/\/www.nice.org.uk\/guidance\/qs138\/resources\/blood-transfusion-pdf-75545425760965. Accessed 29 Mar 2022."},{"key":"23581_CR4","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management. NICE guideline NG203. 2021. https:\/\/www.nice.org.uk\/guidance\/ng203\/resources\/chronic-kidney-disease-assessment-and-management-pdf-66143713055173. Accessed 29 Mar 2022."},{"key":"23581_CR5","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 279\u2013335 (2012)."},{"key":"23581_CR6","first-page":"2030","volume":"70","author":"A Mikhail","year":"2020","unstructured":"Mikhail, A. et al. Clinical practice guideline. Anaemia of chronic kidney disease. The Renal Association. https:\/\/ukkidney.org\/sites\/renal.org\/files\/Updated-130220-Anaemia-of-Chronic-Kidney-Disease-1-1.pdf (2020). Accessed 29 Mar 2022.","journal-title":"Gut"},{"key":"23581_CR7","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1136\/gutjnl-2021-325210","volume":"70","author":"J Snook","year":"2021","unstructured":"Snook, J. et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut 70, 2030\u20132051 (2021).","journal-title":"Gut"},{"key":"23581_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","volume":"9","author":"AU Dignass","year":"2015","unstructured":"Dignass, A. U. et al. European Crohn\u2019s and Colitis Organisation (ECCO). European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J. Crohns. Colitis. 9, 211\u2013222 (2015).","journal-title":"J. Crohns. Colitis."},{"key":"23581_CR9","doi-asserted-by":"crossref","unstructured":"Pavord, S., Daru, J., Prasannan, N., Robinson, S., Stanworth, S., Girling, J., & BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. Br. J. Haematol. 188, 819\u2013830 (2020).","DOI":"10.1111\/bjh.16221"},{"key":"23581_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfv293","volume":"31","author":"PA Kalra","year":"2016","unstructured":"Kalra, P. A. et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol. Dial. Transplant. 31, 646\u2013655 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"23581_CR11","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","volume":"30","author":"S Bhandari","year":"2015","unstructured":"Bhandari, S. et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients. Nephrol. Dial. Transplant. 30, 1577\u20131589 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"23581_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ajh.24633","volume":"92","author":"R Derman","year":"2017","unstructured":"Derman, R. et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am. J. Hematol. 92, 286\u2013291 (2017).","journal-title":"Am. J. Hematol."},{"key":"23581_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/vox.12278","volume":"109","author":"PI Johansson","year":"2015","unstructured":"Johansson, P. I., Rasmussen, A. S. & Thomsen, L. L. Intravenous iron isomaltoside 1000 (Monofer\u00ae) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox. Sang. 109, 257\u2013266 (2015).","journal-title":"Vox. Sang."},{"key":"23581_CR14","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/ajg.2013.335","volume":"108","author":"W Reinisch","year":"2013","unstructured":"Reinisch, W. et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am. J. Gastroenterol. 108, 1877\u20131888 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"23581_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/vox.12477","volume":"112","author":"C Holm","year":"2017","unstructured":"Holm, C., Thomsen, L. L., Norgaard, A. & Langhoff-Roos, J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: A randomized controlled trial. Vox. Sang. 112, 219\u2013228 (2017).","journal-title":"Vox. Sang."},{"key":"23581_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/EJA.0000000000001389","volume":"38","author":"S Yoo","year":"2021","unstructured":"Yoo, S. et al. Efficacy of intra-operative administration of iron isomaltoside for preventing postoperative anaemia after total knee arthroplasty: A randomised controlled trial. Eur. J. Anaesthesiol. 38, 358\u2013365 (2021).","journal-title":"Eur. J. Anaesthesiol."},{"key":"23581_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ajh.25564","volume":"94","author":"M Auerbach","year":"2019","unstructured":"Auerbach, M. et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am. J. Hematol. 94, 1007\u20131014 (2019).","journal-title":"Am. J. Hematol."},{"key":"23581_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","volume":"36","author":"S Bhandari","year":"2021","unstructured":"Bhandari, S. et al. Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol. Dial. Transplant. 36, 111\u2013120 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"23581_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf, M. et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: Two randomized clinical trials. JAMA 323, 432\u2013443 (2020).","journal-title":"JAMA"},{"key":"23581_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/flgastro-2020-101406","volume":"12","author":"J Kearns","year":"2020","unstructured":"Kearns, J. & Jacob, S. G. Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders. Front. Gastroenterol. 12, 265\u2013271 (2020).","journal-title":"Front. Gastroenterol."},{"key":"23581_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12882-020-02180-2","volume":"21","author":"PA Kalra","year":"2020","unstructured":"Kalra, P. A. et al. NIMO-CKD-UK: A real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol. 21, 539 (2020).","journal-title":"BMC Nephrol."},{"key":"23581_CR22","doi-asserted-by":"publisher","first-page":"4585164","DOI":"10.1155\/2017\/4585164","volume":"2017","author":"SO Frigstad","year":"2017","unstructured":"Frigstad, S. O. et al. The NIMO Scandinavian study: A prospective observational study of iron isomaltoside treatment in patients with iron deficiency. Gastroenterol. Res. Pract. 2017, 4585164 (2017).","journal-title":"Gastroenterol. Res. Pract."},{"key":"23581_CR23","unstructured":"Monofer\u00ae (ferric derisomaltose). Summary of product characteristics. Pharmacosmos UK Ltd. 2020. https:\/\/www.medicines.org.uk\/EMC\/medicine\/23669\/SPC\/Monofer+100mg+mL+solution+for+injection+infusion#POSOLOGY. Accessed 29 Mar 2022."},{"key":"23581_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5414\/CN109474","volume":"91","author":"G Jensen","year":"2019","unstructured":"Jensen, G., G\u00f8ransson, L. G., Fernstr\u00f6m, A., Furuland, H. & Christensen, J. H. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia). Clin. Nephrol. 91, 246\u2013253 (2019).","journal-title":"Clin. Nephrol."},{"key":"23581_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00404-020-05509-2","volume":"301","author":"J Wesstr\u00f6m","year":"2020","unstructured":"Wesstr\u00f6m, J. Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy. Arch. Gynecol. Obstet. 301, 1127\u20131131 (2020).","journal-title":"Arch. Gynecol. Obstet."},{"key":"23581_CR26","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ajh.26015","volume":"96","author":"M Wolf","year":"2021","unstructured":"Wolf, M. et al. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA\/NEPHRO trials. Am. J. Hematol. 96, E11-14 (2021).","journal-title":"Am. J. Hematol."},{"key":"23581_CR27","first-page":"296","volume":"12","author":"M Auerbach","year":"2014","unstructured":"Auerbach, M. & Macdougall, I. C. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 12, 296\u2013300 (2014).","journal-title":"Blood Transfus."},{"key":"23581_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/asheducation-2016.1.57","volume":"2016","author":"M Auerbach","year":"2016","unstructured":"Auerbach, M. & Deloughery, T. Single-dose intravenous iron for iron deficiency: A new paradigm. Hematol. Am. Soc. Hematol. Educ. Program. 2016, 57\u201366 (2016).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"23581_CR29","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1111\/bph.13268","volume":"172","author":"J Szebeni","year":"2015","unstructured":"Szebeni, J. et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br. J. Pharmacol. 172, 5025\u20135036 (2015).","journal-title":"Br. J. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23581-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T11:53:57Z","timestamp":1667822037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23581"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23581-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. has received research funding in competitive application for investigator-led research in 2019 from Pharmacosmos. R.S. and N.K. have received honorarium from Pharmacosmos. S.N. and M.W. have declared that no conflicts of interest exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18859"}}